The Post-Vitrectomy Lenstatin Study

http://www.mdlinx.com/ophthalmology/clinical-trials/clinical-trial-detail.cfm?NCT_ID=NCT02131194

Specialties:
Physician Assistant: Clinical Pharmacology, Ophthalmology, Ophthalmology: Clinical Pharmacology, Refractive/Eye Surgery; Pharmacy: Other Drugs
Sponsor: Lenstatin LLC
Study Start Date: May 2014

Estimated Completion Date: December 2014

Interventions

  • Dietary Supplement: Lenstatin
  • Drug: Placebo

Inclusion criteria

  • Adults over the age of 18
  • Post pars plana vitrectomy surgery

Exclusion criteria

  • Pediatric patients under the age of 18
  • Pregnant women
  • Hypersensitivity to any of the ingredients in Lenstatin

Study Locations And Contact Information

  • Scott W Tunis MD FACS, Wilmington North Carolina

Description:

To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy.

Lenstatin Launches Into the Eye Care Marketplace

Cataracts are the leading cause of blindness in the world with 90% of patients over the age of 65 exhibiting initial signs of cataract. Symptoms of cataracts include blurred vision, loss of contrast sensitivity, and difficulty driving at night or reading very fine print. Cataracts can occur in patients in their sixties, fifties, and even forties, and there may be a significant interval from the time of diagnosis until elective surgery.

Lenstatin™ is the first nutraceutical supplement specifically formulated to support the health of the human crystalline lens for patients with early cataract formation. It contains a Unique Proprietary Antioxidant Blend which is not reproduced by other dietary supplements.

Lenstatin LLC was founded by Scott W. Tunis MD FACS to develop ocular disease specific nutraceuticals. Dr. Tunis is a Board Certified Fellow of The American Academy of Ophthalmology, a Fellow of The American College of Surgeons, a member of The American Society of Cataract and Refractive Surgery,  holder of two United States Patents in eye surgery technology, and has performed more than 25,000 cataract operations.

According Dr. Tunis, “It is generally accepted within the scientific community that antioxidants have beneficial effects in a wide array of chronic diseases.  An emerging body of scientific data also suggests that nutritional supplementation with targeted combinations of antioxidants may support the health of individual organ systems, and may be of benefit in the disease states occurring in those systems. As a notable example, nutritional supplements targeted to protect the retina have been statistically shown to slow the progression of macular degeneration. Lenstatin is formulated to target and promote the health of the crystalline lens, which is the site of cataract development.”

“Although no nutritional supplement should replace ongoing professional examination or treatment, patients wanting to promote the health of their eyes in the setting of a developing cataract should maintain a healthy lifestyle and diet, avoid prolonged UV exposure, and consider initiating nutritional supplementation with a high quality targeted formula such as Lenstatin.”